XARELTA 2.5 Tablet

About XARELTA 2.5 Tablet

Made by Opsonin Pharma Limited, XARELTA 2.5 is a tablet whose active ingredient is Rivaroxaban. It is an oral anticoagulant, sometimes called a blood thinner.

There are 19 brands of Rivaroxaban listed in Bangladesh. 1 of them has a lower unit price than XARELTA 2.5. The lowest listed price is Rivadel 2.5 Tablet at ৳ 5 per unit.

What is XARELTA 2.5 Tablet?

XARELTA 2.5 is a tablet from Opsonin Pharma Limited, with the generic name Rivaroxaban. XARELTA 2.5 is a film-coated tablet that contains Rivaroxaban 2.5 mg. Because this medicine affects clotting, it should only be taken on a doctor's advice, and the doctor chooses the dose and how long it is used. Use it only as your doctor directs.

Uses of XARELTA 2.5

It is an oral anticoagulant, sometimes called a blood thinner. XARELTA 2.5 is used in adults to lower the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, and in the treatment of deep vein thrombosis and pulmonary embolism. It is an oral anticoagulant and is not meant for self-treatment. Always follow your doctor's advice about why and for how long you need it.

How to use XARELTA 2.5

The tablet is swallowed, and the doctor will say whether to take it with food and at what time of day. XARELTA 2.5 is taken by mouth. Swallow the tablet with water. Do not take more than prescribed. If you forget a dose, ask your doctor or pharmacist what to do.

Side effects of XARELTA 2.5

Call your doctor promptly if you notice unusual or prolonged bleeding, or any sign of neurological problems such as weakness or numbness. The most common side effect of Rivaroxaban is a greater chance of bleeding, which may appear as bruising, nosebleeds or bleeding gums, or bleeding that is hard to stop. Bleeding may appear as bruising, nosebleeds, gum bleeding or blood in the urine or stool, and in some cases it can be serious. Tell your doctor promptly about any unusual or persistent bleeding, or any new symptoms.

Safety and precautions

It is a pregnancy category C medicine, and there are no adequate studies in pregnancy or breastfeeding, so tell your doctor if you are pregnant, planning pregnancy or breastfeeding. Rivaroxaban is a pregnancy category C medicine, and dosing in pregnancy has not been established; it is not known whether it passes into breast milk, and safety in breastfeeding has not been established. Tell your doctor about all the other medicines you take.

Frequently asked questions

Why is XARELTA 2.5 prescribed?

It is an oral anticoagulant, sometimes called a blood thinner. XARELTA 2.5 is used in adults to lower the risk of stroke and systemic embolism in nonvalvular atrial fibrillation, and in the treatment of deep vein thrombosis and pulmonary embolism.

How do I use XARELTA 2.5 correctly?

The tablet is swallowed, and the doctor will say whether to take it with food and at what time of day. XARELTA 2.5 is taken by mouth.

What are the side effects of XARELTA 2.5?

Call your doctor promptly if you notice unusual or prolonged bleeding, or any sign of neurological problems such as weakness or numbness. The most common side effect of Rivaroxaban is a greater chance of bleeding, which may appear as bruising, nosebleeds or bleeding gums, or bleeding that is hard to stop.

Is XARELTA 2.5 safe for everyone?

It is a pregnancy category C medicine, and there are no adequate studies in pregnancy or breastfeeding, so tell your doctor if you are pregnant, planning pregnancy or breastfeeding. Rivaroxaban is a pregnancy category C medicine, and dosing in pregnancy has not been established; it is not known whether it passes into breast milk, and safety in breastfeeding has not been established.

Indications

Rivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg ... Read moreRivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg:
  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • Deep vein thrombosis (DVT) & pulmonary embolism (PE) and reduction in the risk of recurrence of DVT and of PE
  • For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Pharmacology

Rivaroxaban is a highly selective direct factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibits thrombin formation. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Dosage & Administration

Rivaroxaban 2.5 mg:
  • The recommended dose: 2.5 mg twice daily. Patients should also take a daily dose of 75-100 mg Aspirin or a daily dose of 75-100 mg Aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.
Rivaroxaban 10-20 mg:
  • Nonvalvular Atrial Fibrillation: For patients with Creatinin Clearance >50 mL/min: 20 mg orally, once daily with the evening meal. For patients with Creatinin Clearance 15-50 ml/min: 15 mg orally, once daily with the evening meal.
  • Treatment of DVT & PE: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment.
  • Prevention in the risk of recurrence of DVT and of PE: 20 mg once daily with food.
  • Prophylaxis of DVT following Hip replacement surgery: 10 mg once daily for 35 days.
  • Prophylaxis of DVT following knee replacement surgery: 10 mg once daily for 12 days.
May be taken with or without food.

Interaction

Concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole, diltiazem, verapamil, dronedarone) increases in Rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation), that’s why should be avoided. Co-administration of Rivaroxaban with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin, carbamazepine) decreases the efficacy of Rivaroxaban and also should be avoided. The concomitant use of other drugs like anti-platelet agents, heparin, fibrinolytic therapy, NSAIDs may cause an increased risk of bleeding.

Contraindications

It is contraindicated in patients with known hypersensitivity of Rivaroxaban or any of the excipients of the product. It is also contraindicated in patients with active pathological bleeding.

Side Effects

The most common side effects of Rivaroxaban have increased chance of bleeding, spinal or epidural hematoma and increased risk of stroke after discontinuation in nonvalvular atrial fibrillation.

Pregnancy & Lactation

Rivaroxaban is a pregnancy category C drug. There are no adequate or well-controlled studies of Rivaroxaban in pregnant women, and dosing for pregnant women has not been established. It is not known if Rivaroxaban is excreted in human milk. The safety and efficacy of Rivaroxaban has not been established in breastfeeding women.

Precautions & Warnings

Early discontinuation of Rivaroxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. Rivaroxaban increases the risk of bleeding that can be fatal in presence of following risk factors- bleeding disorders, uncontrolled severe arterial hypertension, gastrointestinal disease (e.g., inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease), vascular retinopathy, bronchiectasis, history of pulmonary bleeding. Signs or symptoms of neurological impairment should be monitored in case of neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture as epidural or spinal hematoma can occur. Rivaroxaban is not recommended in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

Overdose Effects

Overdose of Rivaroxaban may lead to hemorrhage. Rivaroxaban systemic exposure is not further increased at single doses >50 mg due to limited absorption. A specific antidote for Rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of Rivaroxaban overdose may be considered. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.

Storage Conditions

Store in a cool (below 30°C) & dry place protected from light. Keep away from the reach of children.

Alternative brands of Rivaroxaban

Other brands with the same generic name, cheapest first.

See all 19 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.